By harnessing the synergistic power of GLP-1 and Gcg receptor activation, these agents go beyond glucose lowering and weight loss, unlocking new frontiers in energy expenditure, fat oxidation, and liver fat reduction—key targets in conditions such as metabolic dysfunction-associated steatotic liver disease (MASLD). This evidence concerns the gene GCG and metabolic dysfunction-associated steatotic liver disease.